Latest Healthcare It News

Betashares’ newly launched FTSE Global Infrastructure Shares Currency Hedged ETF reported $1.204 billion in profit and $8.08 billion in net assets for its first reporting year. The audited results also show strong gains across several established funds, alongside sharp post-year-end NAV movements in energy and gold miners.

HealthCo Healthcare and Wellness REIT (ASX: HCW) reported a $49.7 million FY26 statutory loss, suspended distributions and received an unmodified audit opinion that nevertheless highlighted a material uncertainty over its ability to continue as a going concern. The key unresolved issue is the transfer of 10 Healthscope hospitals to alternative operators.

GWA Group delivered its third consecutive year of volume growth in FY26, lifting revenue, normalised EBIT and its fully franked dividend despite weak housing and renovation conditions. The trade-off was a sharp decline in operating cash flow and higher net debt following inventory purchases and a $25 million share buyback.

Sonic Healthcare delivered a strong FY2026, with underlying net profit up 17% to A$621 million and dividends rising to A$1.08 per share. The next test is whether US efficiencies, LADR synergies and organic growth can offset Swiss fee cuts, a delayed UK contract ramp-up and heavier investment demands.

Nexsen has paused its StrepSure clinical programme after an interim review identified performance improvements needed before a US FDA submission, pushing the target timetable back by roughly one quarter. Its shares were then suspended pending an announcement about a potentially material contract for an additional device.

Carlton Investments increased FY2026 profit and fully franked dividends, but its investment portfolio underperformed sharply as its largest holding, EVT, fell 22.6% in value. The company’s total portfolio return was negative 3.2%, compared with a 6.1% gain for the S&P/ASX 200 Accumulation Index.

Vection Technologies has signed reciprocal five-year reseller agreements with Xerox, opening a potential Western European channel for its conversational AI, digital human, kiosk and XR technologies. The opportunity is strategically notable, but the agreements contain no minimum volumes, pricing or committed revenue.

PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.

Synertec has raised its FY27 revenue guidance by $8.0 million to $8.3 million, pointing to stronger contract conversion and visibility across its Engineering and Powerhouse businesses. The upgrade follows the $45.5 million ANSTO nuclear medicine manufacturing contract, but covers revenue only and not earnings or cash flow.

Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.